Pylori Duo for Adjunctive Treatment and Prevention of Recurrence of Helicobacter Pylori Infection
A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Pylori Duo as an Adjunctive Treatment and for the Prevention of Recurrence of Helicobacter Pylori Infection
연구 개요
상태
상세 설명
This is a randomized, double-blind, placebo-controlled, single-center interventional clinical trial designed to evaluate the efficacy and safety of Pylori Duo as an adjunctive treatment in adult patients with confirmed Helicobacter pylori infection. Approximately 140 patients aged 18 to 70 years with a positive 13C-urea breath test and gastric biopsy performed before study initiation will be enrolled.
Participants will be randomly assigned to one of two parallel treatment groups. Group A will receive standard quadruple therapy consisting of omeprazole plus Pylera® in combination with placebo for 10 days, followed by placebo for 3 months. Group B will receive the same standard quadruple therapy in combination with Pylori Duo for 10 days, followed by Pylori Duo for 3 months. Both investigators and participants will remain blinded to treatment allocation throughout the study.
The primary objective of the study is to evaluate the effect of Pylori Duo on the management of gastrointestinal adverse effects associated with standard eradication therapy. Secondary objectives include evaluation of H. pylori eradication rate, recurrence of infection at 3 and 12 months after treatment, gastrointestinal symptoms assessed using the Gastrointestinal Symptom Rating Scale (GSRS), gastrointestinal quality of life assessed using the Nepean Dyspepsia Index-Short Form (NDI-SF), and safety and tolerability. Safety assessments will include the recording of adverse events, evaluation of their potential relationship to the study product, and treatment adherence monitoring.
Participants will attend scheduled follow-up visits during treatment and post-treatment follow-up. A 13C-urea breath test will be performed 6 to 8 weeks after completion of Phase I treatment to assess eradication. Follow-up will continue for 3 months after treatment completion, and a telephone assessment will be conducted at 12 months to evaluate recurrence. Statistical analyses will be performed using both intention-to-treat and per-protocol populations.
연구 유형
등록 (추정된)
단계
- 해당 없음
연락처 및 위치
연구 연락처
- 이름: Juan Antonio Carrillo, Medicine
- 전화번호: +34 647725527
- 이메일: carrillo@unex.es
연구 장소
-
-
Badajoz
-
Don Benito, Badajoz, 스페인, 06400
- GALA Laboratories
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
설명
Inclusion Criteria:
- Adults aged 18 to 70 years.
- Confirmed Helicobacter pylori infection prior to treatment, as determined by a positive 13C-urea breath test (13C-UBT) and gastric biopsy.
- No previous H. pylori eradication therapy.
- Ability and willingness to provide written informed consent.
Exclusion Criteria:
- Significant underlying conditions that, in the opinion of the treating physician, would preclude participation in the study, including hepatic insufficiency (aspartate aminotransferase or alanine aminotransferase >3 times the upper limit of normal), renal insufficiency (creatinine ≥2.0 mg/dL or glomerular filtration rate <50 mL/min), immunosuppression, malignant tumors, coronary heart disease or coronary artery stenosis ≥75%, thyroid disease, pulmonary disease, or any other serious medical condition.
- Pregnancy, breastfeeding, or unwillingness to use contraception during the study.
- Active gastrointestinal bleeding.
- History of upper gastrointestinal tract surgery.
- History of allergic reactions to medications included in the treatment regimen.
- Use of bismuth-containing agents, antibiotics, proton pump inhibitors, or other relevant medications within 4 weeks prior to treatment.
- Behaviors that may increase the risk of illness, including excessive alcohol consumption or substance abuse.
- Negative repeat urea breath test prior to treatment initiation.
- Unwillingness or inability to provide informed consent.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 더블
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
위약 비교기: Standard Quadruple Therapy + Placebo
Participants assigned to this arm will receive standard quadruple therapy consisting of omeprazole plus Pylera® in combination with placebo for 10 days during Phase I, followed by placebo for 3 months during Phase II.
|
Omeprazole will be administered as part of the standard quadruple eradication therapy for Helicobacter pylori infection during the 10-day treatment phase.
Pylera® will be administered in combination with omeprazole as part of the standard quadruple eradication therapy for Helicobacter pylori infection during the 10-day treatment phase.
Placebo capsules identical in appearance to Pylori Duo, but without pharmacologically active ingredients, will be administered in combination with standard quadruple therapy for 10 days, followed by placebo for 3 months during the post-treatment phase.
|
|
실험적: Standard Quadruple Therapy + Pylori Duo
Participants assigned to this arm will receive standard quadruple therapy consisting of omeprazole plus Pylera® in combination with Pylori Duo for 10 days during Phase I, followed by Pylori Duo for 3 months during Phase II.
|
Omeprazole will be administered as part of the standard quadruple eradication therapy for Helicobacter pylori infection during the 10-day treatment phase.
Pylera® will be administered in combination with omeprazole as part of the standard quadruple eradication therapy for Helicobacter pylori infection during the 10-day treatment phase.
Pylori Duo is a dietary supplement containing Lactobacillus rhamnosus and dried licorice extract.
Participants assigned to the experimental arm will receive Pylori Duo in combination with standard quadruple therapy for 10 days, followed by Pylori Duo for 3 months during the post-treatment phase.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Gastrointestinal adverse effects associated with standard eradication therapy
기간: Up to 3 months after treatment initiation
|
Assessment of the effect of Pylori Duo on the management of gastrointestinal adverse effects associated with standard Helicobacter pylori eradication therapy.
Gastrointestinal tolerability will be evaluated during the treatment period and follow-up.
|
Up to 3 months after treatment initiation
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Helicobacter pylori eradication rate
기간: 6 to 8 weeks after completion of the 10-day treatment phase
|
Eradication of H. pylori will be assessed by negative 13C-urea breath test performed 6 to 8 weeks after completion of Phase I treatment.
Gastric biopsy may also be considered according to protocol-defined diagnostic assessment.
|
6 to 8 weeks after completion of the 10-day treatment phase
|
|
Recurrence of Helicobacter pylori infection
기간: 3 months and 12 months after completion of treatment
|
Recurrence of H. pylori infection will be evaluated during follow-up at 3 and 12 months after treatment based on post-treatment clinical assessment and protocol-defined follow-up procedures.
|
3 months and 12 months after completion of treatment
|
|
Change from baseline in Gastrointestinal Symptom Rating Scale overall score
기간: Baseline and 3 months after treatment initiation
|
Gastrointestinal symptoms will be assessed using the 15-item Gastrointestinal Symptom Rating Scale.
Each item is scored from 1, indicating no troublesome symptoms, to 7, indicating very troublesome symptoms.
The overall score is calculated as the mean of the 15 item scores and ranges from 1 to 7. Higher scores indicate greater gastrointestinal symptom severity and therefore a worse outcome.
Change from baseline will be evaluated during the follow-up period.
|
Baseline and 3 months after treatment initiation
|
|
Change from baseline in Short Form Nepean Dyspepsia Index total score
기간: Baseline and 3 months after treatment initiation
|
Gastrointestinal health-related quality of life will be assessed using the 10-item Short Form Nepean Dyspepsia Index.
The total score ranges from 0 to 100.
Higher scores indicate better gastrointestinal health-related quality of life and therefore a better outcome.
Change from baseline will be evaluated during the follow-up period.
|
Baseline and 3 months after treatment initiation
|
|
Participants with adverse events
기간: Up to 3 months after the first dose
|
Number and percentage of participants who experience at least one adverse event during the assessment period.
|
Up to 3 months after the first dose
|
|
Participants with study product-related adverse events
기간: Up to 3 months after the first dose
|
Number and percentage of participants who experience at least one adverse event considered by the investigator to be related to the study product.
|
Up to 3 months after the first dose
|
|
Treatment adherence
기간: Up to 3 months after the first dose
|
Treatment adherence will be reported as the percentage of prescribed study product doses taken.
The percentage will be calculated as the number of doses taken divided by the number of doses prescribed, multiplied by 100.
Higher percentages indicate greater treatment adherence.
|
Up to 3 months after the first dose
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Sergio Chamorro Benítez, Medicine, Hospital Parque Vegas Altas, Don Benito (Badajoz)
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
- 20260836
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .